Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;45(6):2561-2578.
doi: 10.1007/s10072-024-07350-w. Epub 2024 Feb 3.

A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives

Affiliations

A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives

Giacomo Sferruzza et al. Neurol Sci. 2024 Jun.

Erratum in

Abstract

High-grade gliomas (HGGs) constitute the most common malignant primary brain tumor with a poor prognosis despite the standard multimodal therapy. In recent years, immunotherapy has changed the prognosis of many cancers, increasing the hope for HGG therapy. We conducted a comprehensive search on PubMed, Scopus, Embase, and Web of Science databases to include relevant studies. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Fifty-two papers were finally included (44 phase II and eight phase III clinical trials) and further divided into four different subgroups: 14 peptide vaccine trials, 15 dendritic cell vaccination (DCV) trials, six immune checkpoint inhibitor (ICI) trials, and 17 miscellaneous group trials that included both "active" and "passive" immunotherapies. In the last decade, immunotherapy created great hope to increase the survival of patients affected by HGGs; however, it has yielded mostly dismal results in the setting of phase III clinical trials. An in-depth analysis of these clinical results provides clues about common patterns that have led to failures at the clinical level and helps shape the perspective for the next generation of immunotherapies in neuro-oncology.

Keywords: Cancer vaccines; Dendritic cell vaccination; Glioblastoma; Immune checkpoint inhibitors; Immunotherapy; Neuro-oncology.

PubMed Disclaimer

References

    1. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251 - PubMed - PMC - DOI
    1. Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:1073–1113 - PubMed - PMC - DOI
    1. Ostrom QT, Price M, Neff C et al (2023) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro Oncol 25:iv1–iv99 - PubMed - DOI
    1. Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186 - PubMed - DOI
    1. Ostrom QT, Shoaf ML, Cioffi G et al (2023) National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25:799–807 - PubMed - DOI

Publication types

Substances

LinkOut - more resources